Prevalence of asymptomatic SARS-CoV-2-positive individuals in the general population of northern Italy and evaluation of a diagnostic serological ELISA test: a cross-sectional study protocol.
Adult
Antibodies, Viral
/ blood
Asymptomatic Infections
/ epidemiology
Betacoronavirus
COVID-19
Child
Clinical Protocols
Coronavirus Infections
/ blood
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay
/ methods
Humans
Immunoglobulins
/ blood
Italy
Mass Screening
/ methods
Pandemics
Pneumonia, Viral
/ blood
Prevalence
Research Design
SARS-CoV-2
Sensitivity and Specificity
Serologic Tests
/ methods
Severe Acute Respiratory Syndrome
diagnostic microbiology
epidemiology
molecular diagnostics
public health
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
06 10 2020
06 10 2020
Historique:
entrez:
8
10
2020
pubmed:
9
10
2020
medline:
30
10
2020
Statut:
epublish
Résumé
As of 30 April 2020, the novel betacoronavirus SARS-CoV-2 had infected more than 3 172 000 individuals, killing over 224 000 people and spreading to more than 200 countries. Italy was the most affected country in Europe and the third most affected in the world in terms of the number of cases. Therefore, the aims of this study are: (1) to estimate the prevalence of asymptomatic SARS-CoV-2-positive individuals among the general population of Verona; (2) to assess the accuracy (sensitivity, specificity and predictive values) of an ELISA serological test for the screening of SARS-CoV-2. The study will be carried out on a random sample of subjects aged at least 10 years from the general population of Verona. Participants will undergo the measurement of vital parameters (oxygen saturation measured by oximeter, respiratory rate and body temperature detected by laser thermometer), the administration of a COVID-19-related symptoms questionnaire, the collection of a blood sample and a nasopharyngeal swab. Our evaluation will include the statistical technique of Latent Class Analysis, which will be the basis for the estimation of prevalence. The study protocol has been approved by the Ethics Committee of Verona and Rovigo provinces on 15 April 2020 (internal protocol number 2641CESC). The study results will be submitted for publication in international, peer-reviewed journals and the complete dataset will be deposited in a public repository. Most relevant data will be made available to policy-makers as well as disseminated to stakeholders and to the community.
Identifiants
pubmed: 33028562
pii: bmjopen-2020-040036
doi: 10.1136/bmjopen-2020-040036
pmc: PMC7539547
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulins
0
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e040036Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Int J Infect Dis. 2020 May;94:154-155
pubmed: 32179137
PLoS Negl Trop Dis. 2017 Jun 5;11(6):e0005593
pubmed: 28582412
J Clin Med. 2020 May 21;9(5):
pubmed: 32455807
J Clin Virol. 2020 Aug;129:104511
pubmed: 32593133
J Clin Epidemiol. 2009 Aug;62(8):797-806
pubmed: 19447581
BMJ. 2018 Jan 18;360:j5779
pubmed: 29348126
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):377-381
pubmed: 32240128
Stat Methods Med Res. 2000 Jun;9(3):231-48
pubmed: 11084706
PLoS Negl Trop Dis. 2015 Feb 10;9(2):e0003491
pubmed: 25668740
JAMA. 2020 Apr 7;323(13):1313-1314
pubmed: 32058570
Health Technol Assess. 2007 Dec;11(50):iii, ix-51
pubmed: 18021577
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930
Clin Infect Dis. 2020 Mar 28;:
pubmed: 32221519
J Vet Sci. 2010 Jun;11(2):165-7
pubmed: 20458159
BMJ Open. 2016 Nov 14;6(11):e012799
pubmed: 28137831
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220